FDA Warns Drug Manufacturers of Recalls due to BCC Contamination

May 31, 2017

FDA reminds drug mfg. of ways to reduce risk of BBC contamination

On Monday, May 22nd, the FDA issued a warning for drug manufacturers regarding the contamination risk posed by Burkholderia cepacia complex (BCC).  According to FDA’s warning, “BCC and other water-borne opportunistic pathogens are among the contaminants that can be found in pharmaceutical water systems.”  As such, BCC contamination has been the cause of numerous recalls regarding non-sterile water-based drug products.

Exposure to BBC can increase a person’s risk of illness or infection, especially if the individual suffers from a compromised immune system.  Because of this, it is extremely important that BBC contamination be identified and corrected as soon as possible.  However, “BCC can survive or multiply in a variety of non-sterile and water-based products because it is resistant to certain preservatives and antimicrobial agents.”  Furthermore, detecting the bacteria is very difficult, often requiring the use of validated testing methods that consider the unique characteristics of different strains of BBC.

In an attempt to reduce the occurrence of BBC contamination, FDA’s warning provides a number of reminders and recommendations for drug makers consider during the manufacturing process.  For details on FDA’s recommendations, view the Agency’s recent announcement.

FDA is asking individuals who experience adverse events or quality problems while using any non-sterile water-based drug product to submit a report to the MedWatch Adverse Event Reporting program.  Adverse events may be reported in the following ways:

  1. Complete and submit the report online at www.fda.gov/medwatch/report.htm; or
  2. Download and complete the form, then submit it via fax at 1-800-FDA-0178.
Do you manufacture a non-sterile water-based drug product or any other FDA-regulated product? Our quality & compliance group can help ensure that your manufacturing processes are compliant with all FDA regulations and requirements.  To learn more about our services and capabilities, contact us today.

Agency Alerts General Regulatory

November 4, 2015

Progesterone Draft Guidance: Recommended Studies to Document Bioequivalence

On Friday, October 30, 2015, FDA released a draft guidance, entitled “Bioequivalence Recommendations for Progesterone,” in which the Agency offers product specific guidance on the design of...

Read the Full Article
Quality & Compliance GMP

October 22, 2015

FDA Provides Recommendations on Injectable Drug Dose Labeling

On October 21, 2015, FDA released a draft guidance entitled “Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose,...

Read the Full Article
Quality & Compliance GMP

December 16, 2015

The FDA’s Enforcement of Section 503B of the Federal Food, Drug, and Cosmetic Act

The FDA publishes weekly enforcement reports highlighting drugs that have been recalled during the previous week. Over the past several months these reports have been littered with hundreds of...

Read the Full Article